Amlodipine 10mg Drug Use Investigation
Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Amlodipine (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Pfizer Official(s) and/or principal investigator(s): Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
In this survey, to collect the safety and efficacy information in the subjects who have been
treated with amlodipine 5mg at least 4 weeks in daily practice.
Clinical Details
Official title: Enhanced Dose Norvasc Treatment For Essential Hypertension In Realworld (Norvasc®10mg Drug Use Investigation)
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: The frequency of treatment related adverse events.The achievement rate to Blood Pressure Goal.
Secondary outcome: Treatment related unlisted adverse events in Japanese Package Insert.Risk factors likely to affect the frequency of treatment related adverse events. Risk factors likely to affect the efficacy.
Detailed description:
All the subjects whom an investigator prescribes Amlodipine (Norvasc®) 10mg Tablet should be
registered consecutively until the number of subjects reaches target number in order to
extract patients enrolled into the investigation at random.
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male or female subjects who have been treated with amlodipine 5mg at least 4 weeks
- The subjects who had not achieved target BP
Exclusion Criteria:
- Subjects who have been prescribed amlodipine (Norvasc®) 10mg Tablet before
Locations and Contacts
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: December 2010
Last updated: January 9, 2014
|